This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eva M. Base, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01174719
First received: August 2, 2010
Last updated: April 6, 2015
Last verified: April 2015
August 2, 2010
April 6, 2015
March 2006
February 2010   (Final data collection date for primary outcome measure)
chest tube drainage [ Time Frame: 24 hours ]
Same as current
Complete list of historical versions of study NCT01174719 on ClinicalTrials.gov Archive Site
  • Hemoglobin concentration [ Time Frame: induction of anesthesia = baseline ]
  • Hematocrit value [ Time Frame: induction of anesthesia = baseline ]
  • platelet count [ Time Frame: induction of anesthesia = baseline ]
  • activated clotting time [ Time Frame: induction of anesthesia = baseline ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: induction of anethesia = baseline ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • Hemoglobin concentration [ Time Frame: average 1 hour on cardiopulmonary bypass ]
  • Hematocrit value [ Time Frame: average 1 hour on cardiopulmonary bypass ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: average 1 hour on cardiopulmonary bypass ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • activated clotting time [ Time Frame: average 1 hour on cardiopulmonary bypass ]
  • Hemoglobin concentration [ Time Frame: 30 minutes after arrival ICU ]
  • Hematocrit value [ Time Frame: 30 minutes after arrival ICU ]
  • platelet count [ Time Frame: 30 minutes after arrival ICU ]
  • activated clotting time [ Time Frame: 30 minutes after arrival ICU ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: 30 minutes after arrival ICU ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • Hemoglobin concentration [ Time Frame: 24 hours after surgery ]
  • Hematocrit value [ Time Frame: 24 hours after surgery ]
  • platelet count [ Time Frame: 24 hrs after surgery ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: 24 hrs after surgery ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • Hemoglobin concentration [ Time Frame: induction of anesthesia = baseline ]
  • Hematocrit value [ Time Frame: induction of anesthesia = baseline ]
  • platelet count [ Time Frame: induction of anesthesia = baseline ]
  • activated clotting time [ Time Frame: induction of anesthesia = baseline ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: induction of anethesia = baseline ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • Hemoglobin concentration [ Time Frame: during cardiopulmonary bypass ]
  • Hematocrit value [ Time Frame: during cardiopulmonary bypass ]
  • platelet count [ Time Frame: during cardiopulmonary bypass ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: during cardiopulmonary bypass ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • activated clotting time [ Time Frame: during cardiopulmonary bypass ]
  • Hemoglobin concentration [ Time Frame: arrival ICU ]
  • Hematocrit value [ Time Frame: arrival ICU ]
  • platelet count [ Time Frame: arrival ICU ]
  • activated clotting time [ Time Frame: arrival ICU ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: arrival ICU ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
  • Hemoglobin concentration [ Time Frame: 24 hours after surgery ]
  • Hematocrit value [ Time Frame: 24 hours after surgery ]
  • platelet count [ Time Frame: 24 hrs after surgery ]
  • Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany) [ Time Frame: 24 hrs after surgery ]
    using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)
Not Provided
Not Provided
 
Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery
Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery

The aim of the study is to compare three different regimens for volume replacement during cardiac surgery, e.g. Albumin 5%, Hydroxyethylstarch 130/0.4 (HES) and Ringer-Lactate (RL).

Main Outcome parameters: chest tube drainage and coagulation parameters. The investigators hypothesis is that HES is as safe as Albumin, however less expensive. Whether RL is an even less expensive and as safe alternative has to be shown.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Valvular Heart Disease
  • Coronary Artery Disease
  • Drug: volume replacement
    Hydroxyethylstarch up to 50mL/kg/24 hrs
    Other Names:
    • Voluven
    • HES 130/0.4
  • Drug: Humanalbumin 5%
    Humanalbumin 5% up to 50 mL/kg/24 hours
    Other Name: Humanalbumin 5% Baxter
  • Drug: volume replacement
    up 10 50mL/kg/24 hours
  • Active Comparator: Hydroxyethylstarch
    Intervention: Drug: volume replacement
  • Active Comparator: Humanalbumin
    Intervention: Drug: Humanalbumin 5%
  • Active Comparator: Ringer lactate
    Intervention: Drug: volume replacement
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
240
April 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Valve replacement
  • Coronary bypass surgery

Exclusion Criteria:

  • Severe left ventricular dysfunction
  • Coagulation disorders
Sexes Eligible for Study: All
20 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT01174719
HAHes
Yes
Not Provided
Not Provided
Eva M. Base, Medical University of Vienna
Medical University of Vienna
Not Provided
Principal Investigator: Eva M Base, MD Medical University of Vienna
Medical University of Vienna
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP